Drug price reform drives Korean pharma firms toward certification to delay 45% cuts
AI Summary- Small and medium-sized pharmaceutical companies are pursuing innovative and quasi-innovative certifications.
- 45% is the government’s final generic and post-patent drug price calculation rate.
- Ministry applications opened August 18 and close September 18, with about 100 companies expected to apply.